|
 The United Nations health agency said provision of experimental
Ebola drugs required "informed consent, freedom of choice,
confidentiality, respect for the person, preservation of dignity and
involvement of the community".
The panel met to discuss whether various experimental medicines and
vaccines being developed for Ebola might be used in the outbreak,
despite not having been fully tested or licensed.
The meeting was called after an experimental Ebola drug called ZMapp,
made by U.S. biotech company Mapp Biopharmaceutical, was given to
two American health workers infected with Ebola in Liberia.
"Ebola outbreaks can be contained using available interventions like
early detection and isolation, contact tracing and monitoring, and
adherence to rigorous procedures of infection control," the panel
said in a statement.
[to top of second column] |
"However, a specific treatment or vaccine would be a potent asset to
counter the virus."
(Reporting by Kate Kelland and Stephanie Nebehay, editing by Ben
Hirschler)
[© 2014 Thomson Reuters. All rights
reserved.] Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
